🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06597838
Recruiting Observational

Development and Validation of a Real-time Prediction Model for Acute Kidney Injury in Hospitalized Patients

NCT06597838 · tracked via the Priya Life Science China tracker
Sponsor
Peking University First Hospital
Phase
Observational
Started
2023-02-28
Last updated
2024-09-19

Condition(s) studied

Prediction Model

Study summary

Early prediction of acute kidney injury (AKI) may provide a crucial opportunity for AKI prevention. To date, no prediction model targeting AKI among general hospitalized patients in developing countries has been published. We developed a simple, real-time, interpretable AKI prediction model for general hospitalized patients from a large tertiary hospital in China, and validated it across five independent, geographically distinct, different tiered hospitals.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients (18 years and older) admitted to five hospitals during the study period Exclusion Criteria: * Have less than 2 documented serum creatinine (Scr) measurements during hospitalization * Being diagnosed with end-stage renal disease (ESRD) * Maintained on dialysis or had an initial Scr greater than or equal to 4.0 mg/dL at admission * Developed AKI prior to admission or within 24 hours after admission * Length of stay shorter than 24 hours * Underwent kidney transplantation or nephrectomy during hospitalization * With all Scr measurements lower than or equal to 0.6 mg/dL from 90 days prior to admission until discharge.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University First Hospital Beijing Beijing Municipality Recruiting

More Peking University First Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06597838 on ClinicalTrials.gov ↗ ← All trials in China